Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) announced that its wholly-owned subsidiary KGK Sciences Inc has opened its new clinical research center in London, Ontario, with the aim of accelerating clients' research and drug development needs in the nutraceutical, cannabinoid, hemp, and psychedelic space.
"Our new research center, located in the heart of London, Ontario, will draw upon the strength and heritage of applied research and innovation and will be an ongoing opportunity for ground-breaking research in the fields of nutraceuticals, cannabinoids, hemp and psychedelics with global partners, clients and academics, striving for excellence as we have done over the past 25 years," Wellbeing & KGK CEO Najla Guthrie said in a statement.
"Our goal is to strengthen the fundamental research needed for global innovation and enable the creation of next-generation nutraceuticals and pharmaceuticals," she added.
READ: Wellbeing Digital Sciences posts fiscal 4Q results; projects significant revenue from research and consulting contracts
KGK will host a ceremony on September 29, 2022, to officially open the new, state-of-the-art clinical research facility and celebrate being a leading contract research organization for over 25 years, the mental healthcare company said.
Led by a team of scientific research and regulatory experts, KGK combines cutting-edge clinical science with industry expertise to design clinical trial and claim substantiation strategies customized to meet the needs of its clients.
Having published more than 150 publications, the company is continuously pushing study designs and measurement tools forward in the industry and was most recently published in Frontiers Journal speaking about the assessment and re-evaluation of clinical trial design.
Wellbeing is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research.
Contact the author at jon.hopkins@proactiveinvestors.com